ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77.
ADC Therapeutics SA has described antibody-drug conjugates comprising antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) covalently linked to exatecan through a linker reported to be useful for the treatment of ovarian cancer and non-small-cell lung cancer (NSCLC).
ADC Therapeutics SA has synthesized antibody-drug conjugates comprising antibody targeting neutral amino acid transporter B(0) (SLC1A5; ASCT2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer.
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
Seven deaths and five respiratory-related, treatment-emergent adverse events in a group of 40 aged and very unwell cancer patients rang alarm bells for ADC Therapeutics SA. The company has voluntarily paused enrollment in its phase II Lotis-9 study of Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) for treating previously untreated diffuse large B-cell lymphoma in those who are considered frail or unfit.
Interleukin-13 (IL-13) receptor subunit α2 (IL13RA2), one of the two major receptors for IL-13 is overexpressed in glioblastoma multiforme and other solid tumors and is correlated with poor prognosis.
In a new licensing deal cut with Swedish Orphan Biovitrum AB (Sobi), ADC Therapeutics SA is getting a $55 million up-front payment and could receive $50 million more upon regulatory approval of Zynlonta (loncastuximab tesirine) in third-line diffuse large B-cell lymphoma by the European Commission.
Switzerland’s biotechnology sector maintained its strong investment performance in 2021. The final tally for the year came to CHF3.33 billion (US$3.4 billion), which is almost equivalent to its record-breaking total of CHF3.4 billion for 2020.
Cancer Research UK took a significant hit when its U.K.-wide charity shop chain had to close last year because of the pandemic. But, according to latest figures, its commercial arm could help it to bounce back after seeing its income more than double in the recent biotech boom. The organization reported record levels of investment in its spinout companies, which more than doubled in 2020-2021 compared with the previous year, jumping from £400 million (US$555 million) to £822 million (US$1.14 billion)
LONDON – Iksuda Therapeutics Ltd. sealed its transition from technology licensing company to antibody-drug conjugate (ADC) development specialist, closing a $47 million series A financing to move the lead program, IKS-03, into the clinic.
